Geographic clustering of human T cell
been reported in many other parts of the world. The first case of HTLV-1 associated leukaemia/lymphoma (ATLL) in South East Asia is reported. Contact tracing showed a high incidence of carriers among the relatives.
Case report A 52 year old Chinese woman was referred for evaluation of an abdominal mass and cervical lymphadenopathy. A cervical lymph node was subsequently biopsied. Sections showed the nodal architecture to be completely effaced by neoplastic lymphoid cells which exhibited a high mitotic rate and displayed bizarre shapes with pronounced nuclear variation and multilobation ( fig A) . Immunophenotyping using a panel of monoclonal antibodies applied to cryostat sections of fresh lymph node tissue showed surface expression of CD2, CD8, HLA-DR and CD25 with weak positivity for CD4 and CD7 in the lymphoid cells (figs B-D). The features were compatible with a high grade pleomorphic medium and large cell type, T-cell non-Hodgkin's lymphoma.2
Staging of her disease showed marrow infiltration by similar pleomorphic lymphoid cells and pronounced para-aortic lymphadenopathy. She was treated with combination chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisolone), but she died from progressive disease two months after diagnosis.
In view of the histological findings we tested her serum for the presence of antibodies to HTLV-1. An enzyme linked immunosorbent assay (ELISA) showed reactivity to HTLV-1 viral proteins and Western blot analysis (Diagnostic Biotechnology, Singapore)
showed reactivity to both gag and env HTLV-1 proteins. She was seronegative for antibody to human immunodeficiency virus. A high incidence of HTLV-1 infections among relatives of patients with HTLV-1 associated leukaemia/lymphoma can be expected.' We tested the sera of nine of her relatives. Four (44%) of them had HTLV-1 infections by both enzyme linked immunosorbent assay and Western blot analysis (fig E) In the management of malignant disease resistance to cytotoxic drugs often makes treatment unsuccessful. Interest has developed in studying the possible benefits of inhibiting the activity of P-glycoprotein to circumvent cytotoxic drug resistance.' P-glycoprotein is a 170 kilodalton transmembrane glycoprotein which acts as an energy dependent pump, causing active efflux of structurally hetero-
